Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States

Peer Review reports

Original Submission
17 Feb 2020	Submitted	Original manuscript
8 Mar 2020	Reviewed	Reviewer Report - Sitanshu Sekhar Kar
11 Mar 2020	Reviewed	Reviewer Report - Qiu Li
20 Mar 2020	Author responded	Author comments - Maximilian Sieg
Resubmission - Version 2
20 Mar 2020	Submitted	Manuscript version 2
Publishing
26 Mar 2020	Editorially accepted
21 Apr 2020	Article published	10.1186/s12876-020-01241-y

Back to article page